|
Clinical Perspectives™
Highlights from the Perspectives
in Melanoma XII Conference
Scheveningen/The Hague, the Netherlands, October 2-4, 2008
New Insights Into Melanoma Biology, Pathogenesis, and Epidemiology
Role of X-chromosome in pathogenesis
The GenoMEL report
Impact of Emerging Technologies for Biomarker Development
New technology for identifying circulating tumor cells: Reliable at last?
Tumor infiltrating lymphocytes
Adjuvant Therapy
Updated analysis and discussion of current EORTC trials
STAT signaling and interferon response
Update on DeCOG interferon trials
New biomarkers or prognostic factors in adjuvant therapy trial design
HLA, CTLA-4 polymorphisms and autoimmunity
Advances in Staging and Surgery
AJCC staging: Preview of the factors that may change in 2009
Alternative staging approaches: The role of ultrasound in prospective follow-up
The sentinel node: Rotterdam criteria of tumor load and prognostic false positivity
Drug Resistance in Melanoma
New insights into mechanisms of drug resistance in melanoma
Explorations of novel targets in melanoma to enhance drug effectiveness
Innovative models to determine chemoresistance
Immunotherapy
Novel improvements in dendritic cell-based vaccines for melanoma
Targeted Therapies
Targeted chemotherapy: minimally invasive percutaneous hepatic perfusion
Targeting angiogenesis in melanoma
Reports on Important Ongoing Clinical Trials
CTLA-4 directed antibodies
Elesclomol
Nab-paclitaxel (ABI-007) in metastatic melanoma
Bevacizumab
Thymalfasin
Oblimersen
Abstract Sessions
Dissemination of melanoma cells beyond the sentinel lymph node is the rule and not the exception
Phase II clinical trial with a second-generation, GM-CSF encoding, oncolytic herpesvirus in unresectable stage IIIc and IV melanoma
A phase I/II study to determine the feasibility and efficacy of the triple combination of oblimersen, nab-paclitaxel, and temozolomide in patients with metastatic melanoma and normal LDH
Phase II study of fotemustine plus dacarbazine with dendritic cell vaccines as first-line in Chinese patients of advanced acral lentiginous melanoma
Phase 2 study of LY573636-sodium, a novel anti-cancer compound with a unique mechanism of action, in patients with previously-treated unresectable or metastatic melanoma
Nab-paclitaxel and bevacizumab as first-line therapy in patients with stage IV melanoma
PV-10 chemoablation of cutaneous and subcutaneous metastatic melanoma
Building the Future of Melanoma Care
A Satellite Symposium Sponsored by Schering-Plough
Sentinel node biopsy—Is it worthwhile or not?
Oncogene based treatment decisions: Fact or fiction?
Stage IV melanoma treatment: What is new?
|
